Table 1.
Clinical characteristics, imaging features and pathological features assessed in 48 patients with 48 HCCs
| Parameter | Classification | Value |
|---|---|---|
| Demographics | ||
| Age (year) | Mean ± standard deviation (range) | 60 ± 11 (36–77) |
| Sex | M/F | 35/13 |
| Clinical characteristics | ||
| Aetiology of liver disease | - Hepatitis C virus | - 12 |
| - Hepatitis B virus | - 26 | |
| - Nonalcoholic steatohepatitis | - 1 | |
| - Alcohol | - 2 | |
| - Primary sclerosing cholangitis | - 1 | |
| - Unknown | - 6 | |
| Fibrosis stage* | 0/1/2/3/4 | 3/6/10/13/14 |
| Child-Pugh scores | A/B/C | 41/6/1 |
| Model for End-Stage Liver Disease (MELD) score | Mean ± standard deviation (range) | 8.1 ± 2.3 (6–18) |
| Barcelona clinical liver cancer (BCLC) stage | 0/A/B/C | 11/13/22/2 |
| American Joint Committee on Cancer (AJCC) stage** | T1/T2/T3 | 12/27/6 |
| Type of surgery | Resection/transplant | 46/2 |
| Imaging appearance | ||
| Infiltrative pattern | Y/N | 1/47 |
| Multiple lesions | Y/N | 5/43 |
| Extranodular growth | Y/N | 12/36 |
| Macrovascular invasion | Y/N | 2/46 |
| Tumour necrosis | Y/N | 7/41 |
| Tumour haemorrhage | Y/N | 5/43 |
| Tumour fat content | Y/N | 7/41 |
| Mosaic appearance | Y/N | 19/29 |
| Internal arteries | Y/N | 11/37 |
| Capsule | Y/N | 39/9 |
| T2 hyperintensity | Y/N | 44/4 |
| ADC hypointensity*** | Y/N | 20/27 |
| Wash-in/wash-out | Y/N | 41/7 |
| Hepatobiliary phase hypointensity**** | Y/N | 29/4 |
| Quantitative imaging features (nontexture related) | ||
| Tumour size (cm) | Mean ± standard deviation (range) | 4.2 ± 3.3 (1.0–15) |
| ADC mean (10−3 mm2/s) | Mean ± standard deviation | 1.28 ± 0.35 |
| ADC min (10−3 mm2/s) | Mean ± standard deviation | 0.60 ± 0.39 |
| Enhancement ratio early arterial phase (%) | Mean ± standard deviation | 57.0 ± 55.0 |
| Enhancement ratio late arterial phase (%) | Mean ± standard deviation | 97.0 ± 49.4 |
| Enhancement ratio portal venous phase (%) | Mean ± standard deviation | 92.8 ± 40.3 |
| Enhancement ratio late venous phase (%) | Mean ± standard deviation | 77.6 ± 35.4 |
| Enhancement ratio hepatobiliary phase (%) | Mean ± standard deviation | 50.9 ± 37.0 |
| Pathology features | ||
| Lesion size | Mean ± standard deviation (range) | 4.5 ± 4.2 (0.8–21) |
| Grade | Well/moderately/poorly differentiated | 4/31/13 |
| Microvascular invasion | Y/N | 31/17 |
ADC = apparent diffusion coefficient
*
Fibrosis stage not assessed for 2 patients
**
AJCC stage not assessed for 3 patients
***
No ADC map in 1 patient
****
No HBP in 15 patients